Nov 17, 2025 8:00 am EST Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
Nov 13, 2025 8:00 am EST Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
Nov 11, 2025 8:30 am EST Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
Oct 23, 2025 8:00 am EDT Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
Sep 22, 2025 8:00 am EDT Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
Sep 18, 2025 8:30 am EDT Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Sep 4, 2025 8:00 am EDT Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Aug 27, 2025 8:00 am EDT Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
Aug 12, 2025 8:00 am EDT Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
Jun 25, 2025 8:00 am EDT Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104